

Short communication

Improved chromium-catalyzed allylic oxidation of Δ^5 -steroids with *t*-butyl hydroperoxide

Manolis A. Fousteris^{a,b}, Anna I. Koutsourea^a, Sotiris S. Nikolaropoulos^{a,*},
Abdelkhalek Riahi^b, Jacques Muzart^{b,*}

^a *Laboratory of Medicinal Chemistry, School of Health Sciences, Department of Pharmacy,
University of Patras, 26500 Patras, Greece*

^b *Unité Mixte de Recherche “Réactions Sélectives et Applications”, Boîte no. 44, CNRS-Université de Reims
Champagne-Ardenne, B.P. 1039, 51687 Reims Cedex 2, France*

Received 26 October 2005; received in revised form 2 January 2006; accepted 19 January 2006
Available online 28 February 2006

Abstract

Various chromium^{VI}-catalyzed conditions have been tested to improve the oxidation of Δ^5 -steroids with *t*-BuOOH to their corresponding 5-en-7-ones. The use of PDC or the association of CrO₃ with an amine as the catalyst and CH₂Cl₂ or PhCF₃ as the solvent led usually to the best yields. A minor reaction pathway was the epoxidation of the double bond.
© 2006 Elsevier B.V. All rights reserved.

Keywords: Δ^5 -Steroids; Allylic oxidation; Catalysis; Chromium oxides; *Tert*-butyl hydroperoxide

Allylic oxidation is a significant reaction in organic synthesis [1]. Among the variety of substrates, the oxidation of Δ^5 -steroids to their corresponding 5-en-7-ones has attracted a particular interest since 7-keto- Δ^5 -steroids are known as inhibitors of mammalian steroidal hormones biosynthesis [2] and their antiproliferative and/or cytotoxic properties render them as molecules of potent value for the cancer treatment [3] while these properties may provide sanative effects for other types of diseases [4].

The classical methods for these allylic oxidations involve the use of very large excesses (up to 40 equivalents) of chromium^{VI} reagents [5] which led to considerable amounts of toxic effluents. According to Chidambaram and Chandrasekaran [6] pyridinium dichromate (PDC) [7] independently does not effect allylic oxidation [8] while a combination of PDC and *t*-BuOOH (4 eq. of each) mediates the transformation of cholesteryl acetate (**1a**) into 3 β -acetoxy-5-cholesten-7-one (**2a**) (84% conversion, 68% yield). For environmental and economical points of view, the use of only catalytic amounts of a transition metal has a

greater interest. In fact, oxidations of Δ^5 -steroids to corresponding 7-keto- Δ^5 -steroids with *t*-BuOOH have been carried out in the presence of catalytic quantities of V [9] Cr [10–13] Mn [9,14] Fe [15] Co [9,16] Cu [9,17,18] Mo [15,19] Ru [20] and Bi [21]-based reagents. Nevertheless, the stoichiometric Cr procedures remain used nowadays [22] probably because they require solely cheap commercial reagents and led to good yields.


Having observed that the efficiency and the selectivity of the Cr-catalyzed oxidations of **1a** with *t*-BuOOH depends on the structure of the catalyst and the nature of the solvent [12] we have now tried to improve such reactions using readily available commercial additives and Cr-reagents, i.e. without sophisticated catalysts.

A variety of experimental conditions were firstly used with **1a** as the substrate; some of them are collected in Table 1. The oxidation of **1a**, carried out firstly at room temperature for 25 h in methylene chloride with CrO₃ as the catalyst and a large excess of *t*-BuOOH (7 eq.), led to 48% of **2a** and 4% of a mixture of α - and β -epoxides **3a** (run 1). Since the use of benzotrifluoride as solvent can increase the efficiency of Cr-catalyzed oxidations [23,24] and also the stability of *tert*-butylperoxychromium complexes [25] the experiment was repeated in this solvent, however, without improvement (run 2). Decreasing the amount

* Corresponding authors.

E-mail addresses: snikolar@upatras.gr (S.S. Nikolaropoulos),
jacques.muzart@univ-reims.fr (J. Muzart).

Table 1
Oxidation of cholesteryl acetate^a



Run	Cr catalyst (eq.)	Additive (eq.)	<i>t</i> -BuOOH (eq.)	Solvent	<i>T</i> (°C)	Time (h)	Conv. (%)	Yield (%) ^b	
								2a	3a
1	CrO ₃ (0.05)	No	7	CH ₂ Cl ₂	rt	25	83	48	4
2	CrO ₃ (0.05)	No	7	PhCF ₃	rt	25	81	50	4
3	CrO ₃ (0.05)	No	4	PhCF ₃	rt	70	82	56	18
4	CrO ₃ (0.05)	No	4	PhCH ₃	rt	70	40	18	17
5	CrO ₃ (0.05)	Py ^c (0.1)	7	CH ₂ Cl ₂	rt	31	93	74	3
6	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	rt	31	95	76	3
7	PDC (0.1)	No	7	CH ₂ Cl ₂	rt	24	95	74	Traces
8	PDC (0.1)	No	7	PhCF ₃	rt	24	96	72	Traces
9	PDC (0.1)	No	7	PhCl	rt	24	96	67	4
10	PDC (0.1)	No	7	PhH	rt	64	98	59	7
11	PDC (0.1)	No	4	PhCF ₃	rt	72	91	76	7
12	PDC (0.1)	No	4	PhCH ₃	rt	72	31	20	7
13	CrO ₃ (0.05)	No	7	PhCF ₃	40	24	95	51	3
14	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	40	24	100	72	5
15	CrO ₃ (0.05)	NMI ^d (0.1)	7	PhCF ₃	40	23	100	74	4
16	PDC (0.025)	No	7	CH ₂ Cl ₂	40	50	100	78	Traces
17	PCC (0.05)	No	7	CH ₂ Cl ₂	40	66	60	41	Traces

^a 1 mmol of substrate, 10 ml of solvent.

^b Isolated yields.


^c Py: pyridine.

^d NMI: *N*-methylimidazole.

of *t*-BuOOH to 4 eq. required a longer reaction time, leading to a similar yield of **2a** but with an increasing amount of **3a** (run 3). With toluene as solvent, the conversion of **1a** dropped considerably (run 4). With pyridine as additive, the yield of **2a** increased strongly in both CH₂Cl₂ and PhCF₃ (runs 5 and 6). This observation urged us to test PDC as the catalyst. As expected, conversions and yields were in the same order than with the CrO₃/pyridine mixture (runs 7 and 8) [26]. Under these conditions, toluene and in particular benzene were less suitable solvents (runs 9 and 10). The use of 4 eq. of *t*-BuOOH in PhCF₃ for 72 h led to 91% conversion and 76% of **2a** (run 11), whereas only 31% conversion was attained in PhCH₃ (run 12). Further experiments were carried at 40 °C with 7 eq. of *t*-BuOOH. Again, the addition of pyridine or *N*-methylimidazole to CrO₃ led to a selective allylic oxidation in PhCF₃ (compare runs 14 and 15 to run 13). Interestingly, **2a** was isolated with 78% yield using only 0.025 eq. of PDC in CH₂Cl₂ (run 16), this yield being higher than the one obtained using 4 eq. of both PDC and *t*-BuOOH [6,27]. A low conversion was obtained using a Cr catalyst having a mildly acidic character [28] such as pyridinium chlorochromate (PCC) (run 17).

Under the experimental conditions of run 16, Table 1, replacing the acetoxy group in C-3 position of the substrate by a benzyloxy or a tosyloxy group yielded the corresponding allylic


oxidation products **2b** and **c**, respectively with a similar selectivity (Eq. (1)).



Unfortunately, the oxidation of Δ^5 -steroids differently substituted in the C-17 position (**4a–c**) under the same conditions afforded low yields of the corresponding 5-en-7-ones (Table 2, runs 1, 8, 15). Consequently, various experimental conditions were again examined, the most interesting results being reported in Table 2. As exemplified by these selected results, optimum yields in the 7-keto- Δ^5 -steroids required fitting experimental conditions for each substrate. That has also been observed for the oxidation of 3 β -acetoxy-17 α -aza-D-homo-androst-5-en-17-one (Table 3).

From the above results, it appears that suitable Cr-catalyzed conditions have been disclosed for the effective and selective oxidation of various Δ^5 -steroids into the corresponding 7-keto- Δ^5 -steroids. In some cases, benzotrifluoride is the sol-

Table 2

Oxidation of 3 β -acetoxy-androst-5-en-17-one, 3 β -acetoxy-pregn-5-en-20-one and 3 β -acetoxy-17 β -acetamido-androst-5-ene^a

Run	Cr catalyst (eq.)	Additive (eq.)	<i>t</i> -BuOOH (eq.)	Solvent	<i>T</i> (°C)	Time (h)	Conv. (%)	Yield (%) ^b	
4a: C ₇ /R ² = C=O								5a	6a
1	PDC (0.025)	No	7	CH ₂ Cl ₂	40	50	63	35	4
2	CrO ₃ (0.05)	No	7	CH ₂ Cl ₂	rt	25	85	78	Traces
3	CrO ₃ (0.05)	Py ^c (0.1)	7	CH ₂ Cl ₂	rt	31	91	78	Traces
4	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	rt	31	94	83	Traces
5	PDC (0.1)	No	4	PhCF ₃	rt	72	95	82	Traces
6	CrO ₃ (0.05)	NMI ^d (0.1)	7	PhCF ₃	40	23	100	83	Traces
7	PDC (0.1)	No	7	CH ₂ Cl ₂	rt	24	80	60	6
4b: C ₇ /R ² = C ₇ /H								5b	6b
8	PDC (0.025)	No	7	CH ₂ Cl ₂	40	50	61	29	10
9	CrO ₃ (0.05)	No	7	CH ₂ Cl ₂	rt	25	98	86	Traces
10	CrO ₃ (0.05)	Py ^c (0.1)	7	CH ₂ Cl ₂	rt	31	93	80	Traces
11	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	rt	31	92	78	Traces
12	PDC (0.1)	No	4	PhCF ₃	rt	72	94	80	2
13	CrO ₃ (0.05)	NMI ^d (0.1)	7	PhCF ₃	40	23	100	81	Traces
14	PDC (0.1)	No	7	CH ₂ Cl ₂	rt	24	89	71	2
4c: C ₇ /R ² = C ₇ /NHAc								5c	6c
15	PDC (0.025)	No	7	CH ₂ Cl ₂	40	50	58	38	Traces
16	CrO ₃ (0.05)	No	7	CH ₂ Cl ₂	rt	25	67	50	Traces
17	CrO ₃ (0.05)	Py ^c (0.1)	7	CH ₂ Cl ₂	rt	31	97	71	8
18	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	rt	31	98	89	5
19	PDC (0.1)	No	4	PhCF ₃	rt	72	91	80	8
20	CrO ₃ (0.05)	NMI ^d (0.1)	7	PhCF ₃	40	23	100	84	4
21	PDC (0.1)	No	7	CH ₂ Cl ₂	rt	24	85	70	Traces

^a 1 mmol of substrate, 10 ml of solvent.^b Isolated yields.^c Py: pyridine.^d NMI: *N*-methylimidazole.

vent allowing to reach the best yields. Unfortunately, benzotrifluoride is an expensive solvent. Nevertheless, it is easily recoverable by distillation, especially when the substrate and the corresponding oxidized compounds are not volatile as already reported for the Cr-catalyzed oxidations of alcohols and benzylic methylene groups by sodium percarbonate in PhCF₃ [23].


General procedure

In a round bottom flask containing the catalyst (0.025–0.1 mmol) and the solvent (10 mL) were added 70% aqueous *t*-BuOOH (4–7 mmol) and, after stirring for

1–2 min, the substrate (1 mmol). After stirring under reaction temperature and time conditions indicated in Tables, the mixture was filtered over a small pad of Celite. The solvent was evaporated under reduced pressure and the residue was subjected to flash-chromatography. Elution using EtOAc/petroleum ether mixtures led to the separation of the products.

The different 7-keto- Δ^5 -steroids have been identified by comparison of their spectroscopic data with those of the literature [18]. The epoxides have been identified from their ¹H NMR spectra, the signal at around 3 ppm being characteristic of the hydrogen in the C-6 position [15,19].

Table 3

Oxidation of 3 β -acetoxy-17 α -aza-D-homo-androst-5-en-17-one^a

Run	Cr catalyst (eq.)	Additive (eq.)	<i>t</i> -BuOOH (eq.)	Solvent	<i>T</i> (°C)	Time (h)	Conv. (%)	Yield (%) ^b	
								8	9
1	CrO ₃ (0.05)	No	7	CH ₂ Cl ₂	rt	25	78	34	5
2	CrO ₃ (0.05)	Py ^c (0.1)	7	CH ₂ Cl ₂	rt	31	81	65	Traces
3	CrO ₃ (0.05)	Py ^c (0.1)	7	PhCF ₃	rt	31	90	81	3
4	PDC (0.1)	No	4	PhCF ₃	rt	72	91	74	5
5	CrO ₃ (0.05)	NMI ^d (0.1)	7	PhCF ₃	40	23	100	83	3
6	PDC (0.1)	No	7	CH ₂ Cl ₂	rt	24	91	56	Traces

^a 1 mmol of substrate, 10 ml of solvent.^b Isolated yields.^c Py: pyridine.^d NMI: *N*-methylimidazole.

Acknowledgments

This research was supported by CNRS and the “K. Karathodori” grant no. 3013, Research Committee of the University of Patras, Greece.

References

- J. Muzart, Bull. Soc., Chim. Fr. (1986) 65–77.
- (a) A.A. Kandutsch, H.W. Chen, H.J. Heiniger, Science 201 (1978) 498–501;
(b) M. Numazawa, A. Mutsumi, K. Hoshi, Y. Tanaka, Biochem. Biophys. Res. Commun. 186 (1992) 32–39.
- H. Nagano, J.P. Poyser, K.P. Cheng, L. Bang, G. Ourisson, J. Chem. Res. (S) (1977) 218.
- (a) G. Lizard, S. Lemaire, S. Monier, S. Gueldry, D. Neel, P. Gambert, FEBS Lett. 419 (1997) 276–280;
(b) M. Numazawa, A. Mutsumi, M. Tachibana, K. Hoshi, J. Med. Chem. 37 (1994) 2198–2205.
- (a) G.W. Salmond, M.A. Barta, J.L. Havens, J. Org. Chem. 43 (1978) 2057–2059;
(b) E.J. Parish, S. Chitrakorn, Synth. Commun. 15 (1985) 393–399;
(c) E.J. Parish, S. Chitrakorn, K.L. Todd, Org. Prep. Proc. Int. 17 (1985) 192–194;
(d) E.J. Parish, T.-Y. Wei, Synth. Commun. 17 (1987) 1227–1233;
(e) E.J. Parish, H. Sun, S.A. Kizito, J. Chem. Res. (S) (1996) 544–545;
(f) A. Amann, G. Ourisson, B. Luu, Synthesis (1987) 1002;
(g) F.A. Luzzio, F.S. Guziec, Org. Prep. Proc. Int. 20 (1988) 533–584.
- N. Chidambaram, S. Chandrasekaran, J. Org. Chem. 52 (1987) 5048–5051.
- E.J. Corey, G. Schmidt, Tetrahedron Lett. (1979) 399–402.
- Over-stoichiometric amounts of PDC have been however used for the allylic oxidation of other Δ^5 -steroids;
(a) see ref. 5d;
(b) P.M.F.M. Bastiaansen, L. Kohout, M.A. Posthupus, J.B.P.A. Wijnberg, A.J. de Grost, Org. Chem. 61 (1996) 859–867;
(c) M. Hector, R.W. Hartmann, V.C.O. Njar, Synth. Commun. 26 (1996) 1075–1082.
- J.A.R. Salvador, J.H. Clark, Green Chem. 4 (2002) 352–356.
- J. Muzart, Chem. Rev. 92 (1992) 113–140.
- (a) A.J. Pearson, Y.-S. Chen, S.-Y. Hsu, T. Ray, Tetrahedron Lett. 25 (1984) 1235–1238;
(b) A.J. Pearson, Y.-S. Chen, G.R. Han, S.-Y. Hsu, T. Ray, J. Chem. Soc. Perkin Trans. I (1985) 267–273.
- (a) J. Muzart, Tetrahedron Lett. 28 (1987) 4665–4668;
(b) J. Muzart, New J. Chem. 13 (1989) 9–11;
(c) J. Muzart, Synth. Commun. 19 (1989) 2061–2067.
- L.H.B. Baptistella, I.M.O. Sousa, Y. Gushikem, A.M. Aleixo, Tetrahedron Lett. 40 (1999) 2695–2698.
- R. Prousa, B. Schönecker, J. Prakt. Chem. 333 (1991) 775–777.
- M. Kimura, T. Muto, Chem. Pharm. Bull. 27 (1979) 109–112.
- (a) J.A.R. Salvador, J.H. Clark, Chem. Commun. (2001) 33–34;
(b) J.H. Clark, J.A.R. Salvador, WO 2002016391, 2002; Chem. Abstr (2002) 157798;
(c) M. Jurado-Gonzalez, A.C. Sulliwán, J.R.H. Wilson, Tetrahedron Lett. 44 (2003) 4283–4286.
- (a) J.A.R. Salvador, M.L. Sá e Melo, A.S. Campos Neves, Tetrahedron Lett. 38 (1997) 119–122;
(b) J.A.R. Salvador, M.L. Sá e Melo, A.S. Campos Neves, US 97-901764 (1997); Chem. Abstr. (2001) 464392.
- E.S. Arsenou, A.I. Koutsourea, M.A. Fouteris, S.S. Nikolaropoulos, Steroids 68 (2003) 407–414.
- M. Kimura, T. Muto, Chem. Pharm. Bull. 28 (1980) 1836–1841.
- (a) R.A. Miller, A.S. Thompson, R.K. Bakski, E.G. Corley, WO 9532215 (1995); Chem. Abstr. (1996) 115197;
(b) R.A. Miller, W. Li, G.R. Humphrey, Tetrahedron Lett. 37 (1996) 3429–3432;
(c) M. Harre, R. Haufe, K. Nickisch, P. Weinig, H. Weinmann, Org. Process Res. Dev. 2 (1998) 100–104;
(d) M.E. Jung, T.W. Johnson, Org. Lett. 1 (1999) 1671–1674.
- J.A.R. Salvador, S.M. Silvestre, Tetrahedron Lett. 46 (2005) 2581–2584.
- (a) M. Di Filippo, I. Izzo, L. Savignano, P. Tecilla, F. De Riccardis, Tetrahedron 59 (2003) 1711–1717;
(b) Y. Zheng, Y. Li, J. Org. Chem. 68 (2003) 1603–1606;
(c) V. Pouzar, I. Černý, M. Hill, M. Bičiková, R. Hampl, Steroids 70 (2005) 739–749;
(d) Z. Hua, D.A. Carcache, Y. Tian, Y.-M. Li, S.J. Danishefsky, J. Org. Chem. 70 (2005) 9849–9856.
- N. Delaval, S. Bouquillon, F. Hénin, J. Muzart, J. Chem. Res. (S) (1999) 286–287.
- S. Boitsov, A. Riahi, J. Muzart, C. R. Acad. Sci. Paris, Série IIC 3 (2000) 747–750.

- [25] S. Boitsov, J. Songstad, J. Muzart, J. Chem. Soc., Perkin Trans. II (2001) 2318–2323.
- [26] For the PDC-catalyzed allylic oxidation of a non-steroidal substrate with *t*-BuOOH, see: A.G. Schultz, T.J. Guzi, E. Larsson, R. Rahm, K. Thakkar, J.M. Bidlack, J. Org. Chem. 63 (1998) 7795–7804.
- [27] The high efficiency of low amounts of PDC to catalyze the benzylic oxidation of indane with *t*-BuOOH in CH₂Cl₂ has been already observed: J. Muzart, A. N'Aït Ajjou, J. Mol. Catal. 66 (1991) 155–161.
- [28] E.J. Corey, J.W. Suggs, Tetrahedron Lett. (1975) 2647–2650.